Hope high for "personalised medicine" in melanoma
This article was originally published in Scrip
Executive Summary
Hopes are high that inhibition of the mutated BRAF oncogene, present in about 40-60% of melanomas, will become a strategy for "personalised medicine" in the difficult-to-treat disease, based on the promising results of an early clinical trial of a BRAF kinase inhibitor being developed by Plexxikon and Roche that was just published in the New England Journal of Medicine.